EXEL | Exelixis, Inc.

Index- P/E40.68 EPS (ttm)0.47 Insider Own0.70% Shs Outstand324.42M Perf Week0.05%
Market Cap6.32B Forward P/E20.32 EPS next Y0.94 Insider Trans-12.85% Shs Float315.46M Perf Month-0.93%
Income153.70M PEG1.50 EPS next Q0.15 Inst Own88.10% Short Float / Ratio2.35% / 2.63 Perf Quarter15.11%
Sales1.66B P/S3.80 EPS this Y-21.60% Inst Trans-1.81% Short Interest7.41M Perf Half Y17.43%
Book/sh7.88 P/B2.44 EPS next Y46.51% ROA5.10% Target Price25.40 Perf Year-0.10%
Cash/sh3.99 P/C4.81 EPS next 5Y27.10% ROE6.20% 52W Range14.87 - 22.47 Perf YTD19.70%
Dividend- P/FCF23.82 EPS past 5Y2.60% ROI6.00% 52W High-14.55% Beta0.68
Dividend %- Quick Ratio4.90 Sales past 5Y28.90% Gross Margin96.50% 52W Low29.12% ATR0.42
Employees1223 Current Ratio5.00 Sales Q/Q14.80% Oper. Margin8.80% RSI (14)48.85 Volatility2.07% 2.05%
OptionableYes Debt/Eq0.00 EPS Q/Q-42.20% Profit Margin9.20% Rel Volume1.62 Prev Close19.35
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout0.00% Avg Volume2.82M Price19.20
Recom1.90 SMA20-0.78% SMA50-0.48% SMA2009.72% Volume4,554,794 Change-0.78%
Date Action Analyst Rating Change Price Target Change
May-10-23Resumed Piper Sandler Overweight $28
Mar-09-23Initiated Wells Fargo Overweight $23
Jan-26-23Initiated Credit Suisse Outperform $29
Oct-18-22Initiated JMP Securities Mkt Outperform $26
Jun-24-22Initiated BMO Capital Markets Outperform $28
Nov-19-21Initiated Piper Sandler Overweight $34
Nov-03-21Resumed Jefferies Buy $28
Oct-07-21Initiated Jefferies Buy $28
Aug-06-21Reiterated H.C. Wainwright Buy $35 → $64
Jun-15-21Initiated H.C. Wainwright Buy $47
Jun-08-23 11:30AM
May-31-23 12:30PM
May-30-23 04:05PM
May-29-23 11:58AM
09:53AM Loading…
May-24-23 09:53AM
May-20-23 09:30AM
May-13-23 05:06AM
May-12-23 07:55AM
May-10-23 02:52PM
May-09-23 09:34PM
09:30AM Loading…
May-08-23 09:30AM
May-07-23 11:30PM
May-03-23 04:05PM
May-01-23 05:08PM
Apr-26-23 08:00PM
Apr-25-23 04:05PM
Apr-22-23 06:55AM
Apr-19-23 12:44PM
06:03PM Loading…
Apr-13-23 06:03PM
Apr-11-23 01:32PM
Apr-05-23 06:06PM
Apr-04-23 06:00PM
Mar-31-23 10:10AM
Mar-29-23 11:14AM
Mar-27-23 03:38PM
Mar-24-23 06:57PM
Mar-21-23 05:10PM
Mar-20-23 07:11PM
Mar-18-23 06:14AM
Mar-16-23 03:59PM
Mar-13-23 04:05PM
Mar-11-23 05:06AM
Mar-10-23 10:07AM
Mar-09-23 11:30AM
Mar-06-23 12:40PM
Mar-03-23 02:29PM
Mar-02-23 06:46PM
Mar-01-23 11:46AM
Feb-28-23 04:05PM
Feb-18-23 05:06AM
Feb-14-23 12:01PM
Feb-13-23 05:00PM
Feb-12-23 09:00AM
Feb-09-23 05:38AM
Feb-08-23 12:40PM
Feb-07-23 05:55PM
Feb-06-23 10:30AM
Feb-04-23 09:40AM
Feb-02-23 04:05PM
Feb-01-23 07:46PM
Jan-31-23 10:00AM
Jan-25-23 10:37AM
Jan-24-23 04:05PM
Jan-20-23 01:17PM
Jan-19-23 06:43PM
Jan-18-23 03:44PM
Jan-11-23 07:56AM
Jan-09-23 01:33PM
Jan-08-23 04:00PM
Jan-03-23 07:02PM
Dec-29-22 10:15AM
Dec-25-22 08:30AM
Dec-22-22 08:00AM
Dec-21-22 08:45AM
Dec-19-22 06:46PM
Dec-16-22 05:21AM
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hessekiel JeffreyEVP, General Counsel & SecApr 05Option Exercise14.7413,930205,328621,365Apr 05 08:57 PM
Hessekiel JeffreyEVP, General Counsel & SecApr 05Sale20.0138,930778,989582,435Apr 05 08:57 PM
WYSZOMIERSKI JACK LDirectorMar 10Option Exercise6.3040,000252,000332,767Mar 14 08:22 PM
WYSZOMIERSKI JACK LDirectorMar 10Sale16.6115,300254,133317,467Mar 14 08:22 PM
Hessekiel JeffreyEVP, General Counsel & SecMar 01Option Exercise14.7427,860410,656605,576Mar 03 07:59 PM
Hessekiel JeffreyEVP, General Counsel & SecMar 01Sale17.1377,8601,333,742527,716Mar 03 07:59 PM
Aftab DanaCSO/EVP Disc & Trans ResearchFeb 28Option Exercise14.7482,4901,215,903433,962Mar 01 07:56 PM
Aftab DanaCSO/EVP Disc & Trans ResearchFeb 28Sale17.5082,4901,443,575351,472Mar 01 07:56 PM
Aftab DanaCSO/EVP Disc & Trans ResearchFeb 27Option Exercise14.7410147351,482Mar 01 07:56 PM
Aftab DanaCSO/EVP Disc & Trans ResearchFeb 27Sale17.5010175351,472Mar 01 07:56 PM
Garber Alan MDirectorFeb 21Option Exercise6.3040,000252,00071,417Feb 23 09:08 PM
Garber Alan MDirectorFeb 21Sale17.4940,000699,60031,417Feb 23 09:08 PM
FELDBAUM CARL BDirectorFeb 09Option Exercise6.3040,000252,00058,701Feb 10 07:56 PM
FELDBAUM CARL BDirectorFeb 09Sale17.7840,000711,20018,701Feb 10 07:56 PM
Haley Patrick J.EVP, CommercialFeb 06Option Exercise4.2025,000105,000279,414Feb 08 08:17 PM
Haley Patrick J.EVP, CommercialFeb 06Sale17.3725,000434,250254,414Feb 08 08:17 PM
MORRISSEY MICHAELPresident and CEOJan 24Option Exercise4.20100,000420,000440,655Jan 26 08:59 PM
Lamb PeterEVP, Scientific Strategy & CSODec 15Option Exercise4.2020,00084,000430,958Dec 16 08:09 PM
Lamb PeterEVP, Scientific Strategy & CSODec 15Sale15.8820,000317,600410,958Dec 16 08:09 PM
POSTE GEORGEDirectorNov 29Option Exercise6.3040,000252,000233,189Dec 01 08:11 PM
POSTE GEORGEDirectorNov 29Sale16.6840,000667,200193,189Dec 01 08:11 PM
Haley Patrick J.EVP, CommercialSep 12Option Exercise6.2140,000248,400301,591Sep 14 07:57 PM
Haley Patrick J.EVP, CommercialSep 12Sale17.9440,000717,600261,591Sep 14 07:57 PM
Senner Christopher J.EVP and CFOAug 11Option Exercise6.21225,0001,397,250670,882Aug 12 08:23 PM